Drug Profile
ACT 1
Alternative Names: ACT-1; alpha-Connexin carboxyl-Terminal 1 peptide - Xequel Bio; Granexin Gel; iNexin; αCT1Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator FirstString Research; Medical University of South Carolina
- Developer Medical University of South Carolina; Xequel Bio
- Class Antineoplastics; Eye disorder therapies; Peptide fragments; Skin disorder therapies
- Mechanism of Action Connexin 43 inhibitors; Zonula occludens protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diabetic foot ulcer; Leg ulcer; Radiation injuries; Scars
- Phase II/III Radiodermatitis
- Phase II Burns; Corneal injuries
- Phase I Dry eyes; Eye disorders
- Preclinical Acute lung injury; Adult respiratory distress syndrome
- No development reported Age-related macular degeneration; Corneal disorders; Fibrosis; Glioblastoma; Spinal cord injuries
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Corneal-disorders in USA (Ophthalmic, Drops)
- 10 Feb 2023 Phase-II clinical trials in Corneal injuries in USA (Ophthalmic) (Xequel Bio pipeline; February 2023)
- 10 Feb 2023 Preclinical trials in Acute lung injury in USA (Inhalation) (Xequel Bio pipeline; February 2023)